Literature DB >> 11389050

Molecular identification of latent precancers in histologically normal endometrium.

G L Mutter1, T A Ince, J P Baak, G A Kust, X P Zhou, C Eng.   

Abstract

Discovery of somatically mutated cells in human tissues has been less frequent than would be predicted by in vitro mutational rates. We analyzed the PTEN tumor suppressor gene as an early marker for endometrial carcinogenesis, and we show that 43% of histologically normal premenopausal endometria contain rare glands that fail to express PTEN protein because of mutation and/or deletion. These persist between menstrual cycles. Histopathology of PTEN-null glands is initially unremarkable, but with progression, they form distinctive high-density clusters. These data are consistent with a progression model in which initial mutation is not rate limiting.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11389050

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  46 in total

1.  Evidence of the monoclonal composition of human endometrial epithelial glands and mosaic pattern of clonal distribution in luminal epithelium.

Authors:  Masaaki Tanaka; Satoru Kyo; Taro Kanaya; Noriyuki Yatabe; Mitsuhiro Nakamura; Yoshiko Maida; Masaru Okabe; Masaki Inoue
Journal:  Am J Pathol       Date:  2003-07       Impact factor: 4.307

2.  Joint loss of PAX2 and PTEN expression in endometrial precancers and cancer.

Authors:  Nicolas M Monte; Kaitlyn A Webster; Donna Neuberg; Gregory R Dressler; George L Mutter
Journal:  Cancer Res       Date:  2010-07-14       Impact factor: 12.701

3.  PTEN expression in benign human endometrial tissue and cancer in relation to endometrial cancer risk factors.

Authors:  Hannah P Yang; Alan Meeker; Richard Guido; Marc J Gunter; Gloria S Huang; Patricia Luhn; Lori d'Ambrosio; Nicolas Wentzensen; Mark E Sherman
Journal:  Cancer Causes Control       Date:  2015-09-16       Impact factor: 2.506

4.  Loss of inhibitory insulin receptor substrate-1 phosphorylation is an early event in mammalian target of rapamycin-dependent endometrial hyperplasia and carcinoma.

Authors:  Adrienne S McCampbell; Heather A Harris; Judy S Crabtree; Richard C Winneker; Cheryl L Walker; Russell R Broaddus
Journal:  Cancer Prev Res (Phila)       Date:  2010-02-23

Review 5.  EIN and WHO94.

Authors:  J P A Baak; G L Mutter
Journal:  J Clin Pathol       Date:  2005-01       Impact factor: 3.411

6.  Squamous morules are functionally inert elements of premalignant endometrial neoplasia.

Authors:  Ming-Chieh Lin; Lesley Lomo; Jan P A Baak; Charis Eng; Tan A Ince; Christopher P Crum; George L Mutter
Journal:  Mod Pathol       Date:  2008-09-19       Impact factor: 7.842

7.  Identification of potential serum markers for endometrial cancer using protein expression profiling.

Authors:  Masashi Takano; Yoshihiro Kikuchi; Takayoshi Asakawa; Tomoko Goto; Tsunekazu Kita; Kazuya Kudoh; Junzo Kigawa; Noriaki Sakuragi; Masaru Sakamoto; Toru Sugiyama; Nobuo Yaegashi; Hiroshi Tsuda; Hiroshi Seto; Mieko Shiwa
Journal:  J Cancer Res Clin Oncol       Date:  2009-09-16       Impact factor: 4.553

8.  PTEN mutational spectra, expression levels, and subcellular localization in microsatellite stable and unstable colorectal cancers.

Authors:  Xiao-Ping Zhou; Anu Loukola; Reijo Salovaara; Minna Nystrom-Lahti; Päivi Peltomäki; Albert de la Chapelle; Lauri A Aaltonen; Charis Eng
Journal:  Am J Pathol       Date:  2002-08       Impact factor: 4.307

Review 9.  Declining cellular fitness with age promotes cancer initiation by selecting for adaptive oncogenic mutations.

Authors:  Andriy Marusyk; James DeGregori
Journal:  Biochim Biophys Acta       Date:  2007-10-12

10.  A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations.

Authors:  Ann K Folkins; Elke A Jarboe; Aasia Saleemuddin; Yonghee Lee; Michael J Callahan; Ronny Drapkin; Judy E Garber; Michael G Muto; Shelley Tworoger; Christopher P Crum
Journal:  Gynecol Oncol       Date:  2008-03-14       Impact factor: 5.482

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.